RGNX — REGENXBIO Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1590877 ·
Last close
$7.24
Market Cap
$478.73M
52W High
$16.19
52W Low
$5.45
ADV30
1,305,796
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 9,162,000 | 8,021,000 | -73,560,000 | -40,738,000 | 466,040,000 | 95,795,000 | 317,998,000 |
| Jun 2026 | 108,019,000 | 106,977,000 | 29,263,000 | 22,709,000 | 386,618,000 | 36,487,000 | 314,853,000 |
| Mar 2026 | 6,393,000 | -4,681,000 | -83,362,000 | -90,051,000 | 341,894,000 | 15,229,000 | 320,812,000 |
| Dec 2025 | 30,337,000 | 24,409,000 | -57,636,000 | -67,149,000 | 453,032,000 | 34,466,000 | 350,299,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-152,105,000
Investing CF
$87,898,000
Financing CF
$101,200,000
CapEx
$-2,697,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.21
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,234,107,000
Inventory
—
Receivables
$9,497,000
ST Investments
$155,181,000
EBIT TTM
$-138,980,000
Pretax Income TTM
$-175,229,000
Interest Exp TTM
$36,249,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$153,911,008
EBITDA
$-170,296,992
Free Cash Flow
$-128,852,000
Enterprise Value
$505,102,208
Total Cash
$250,976,000
Total Debt
$252,224,000
Shares Out
66,122,600
Trailing EPS
$-3.20
Book Value
$2.24
ROE
-113.2%
ROA
-23.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 170,441,000 | -161,198,000 | -193,878,000 | 453,032,000 | 350,299,000 | 102,733,000 | -123,963,000 |
| Dec 2024 | 83,328,000 | -231,245,000 | -227,102,000 | 465,989,000 | 206,338,000 | 259,651,000 | -173,125,000 |
| Dec 2023 | 90,242,000 | -268,128,000 | -263,494,000 | 573,970,000 | 262,228,000 | 311,742,000 | -218,407,000 |
| Dec 2022 | 112,724,000 | -262,876,000 | -280,321,000 | 833,268,000 | 317,073,000 | 516,195,000 | -207,488,000 |
TTM Snapshot
Revenues TTM
$174,482,000
NetIncome TTM
$-196,432,000
OpCashFlow TTM
—
Assets (Latest)
$386,618,000
Forward EPS
$-3.06
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $8.00 · spot: $7.26 · call volume: 61 · put volume: 306
Expected Move to 2027-04-16:
±$4.54
(62.53%) —
implied range
$2.72 –
$11.80
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FENC | FENNEC PHARMACEUTICALS INC. | $479.44M | $13.58 | — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $448.81M | $8.32 | — |
| ENTX | Entera Bio Ltd. | $521.77M | $3.00 | — |
| ETRA | Electra Therapeutics, Inc. | $524.10M | $8.35 | — |
| VALN | Valneva SE | $527.69M | $5.57 | — |
News headlines (Yahoo Finance, 1h cache)
Regenxbio Inc (RGNX) (Q3 2026) Earnings Call Highlights: Dual Gene Therapy Catalysts Near ...
2026-11-07 07:33 · Yahoo
REGENXBIO Q3 Earnings Call Highlights
2026-11-06 18:15 · Yahoo
REGENXBIO (RGNX) Q3 2026 Earnings Call Transcript
2026-11-05 19:33 · Yahoo
Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates
2026-11-05 13:35 · Yahoo
Regenxbio: Q3 Earnings Snapshot
2026-11-05 12:32 · Yahoo
REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
2026-11-05 12:05 · Yahoo
Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?
2026-11-04 13:55 · Yahoo
REGENXBIO to Participate in Stifel 2026 Healthcare Conference
2026-11-03 12:05 · Yahoo
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?
2026-10-29 13:00 · Yahoo
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
2026-10-29 11:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.